NASDAQ:BBLG Bone Biologics Q2 2026 Earnings Results & Report $0.47 0.00 (-0.43%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$0.47 +0.00 (+0.62%) As of 10/9/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Bone Biologics missed analyst earnings expectations in its Q2 2026 results, released August 14, 2026. The company reported EPS of -$0.43 versus the -$0.39 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 14, 2026TimeBefore Market Opens Bone Biologics EPS ResultsActual EPS-$0.43Consensus EPS -$0.39Beat/MissMissed by -$0.04One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersBone Biologics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsBone Biologics' next earnings date is estimated for Friday, November 13, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Bone Biologics Q2 2026 Earnings FAQ Did Bone Biologics beat earnings estimates for Q2 2026? Bone Biologics (NASDAQ:BBLG) reported earnings of -$0.43 per share for Q2 2026, missing the consensus estimate of -$0.39. The report was announced on Friday, August 14, 2026. When is Bone Biologics' next earnings date? Bone Biologics' next earnings date is estimated for Friday, November 13, 2026. MarketBeat tracks confirmed and estimated earnings dates for Bone Biologics on the company's earnings history page. Bone Biologics Earnings HeadlinesBone Biologics (NASDAQ:BBLG) Stock Jumps 0.1% - Here's What HappenedOctober 3, 2026 | americanbankingnews.comBone Biologics Expands Trial SitesSeptember 8, 2026 | globenewswire.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.October 10 at 1:00 AM | Porter & Company (Ad)Bone Biologics to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 3, 2026 | globenewswire.comBBLG Efficiency Improves as Crucial Trials AdvanceAugust 17, 2026 | finance.yahoo.comBone Biologics extends rhNELL-1 validated shelf life to 32 months as NB1 study advancesAugust 12, 2026 | msn.comSee More Bone Biologics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Bone Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bone Biologics and other key companies, straight to your email. Email Address About Bone BiologicsBone Biologics (NASDAQ:BBLG) Corporation (NASDAQ: BBLG) is a biotechnology company focused on developing regenerative medicine products for the orthopedic and spine markets. Its work centers on bone growth and spinal fusion, where physicians use biologic materials and implants to help stabilize the spine and support the formation of new bone. The company’s primary technology is based on NELL-1, a recombinant human protein that has demonstrated bone-forming properties in preclinical and clinical research. Bone Biologics has been developing NELL-1-based products, including bone graft substitutes intended for use with spinal fusion procedures. The company’s strategy is to combine its biologic technology with established scaffold materials and delivery systems to create products designed to promote bone regeneration. Bone Biologics has historically operated as a development-stage biotechnology company and has focused its research and commercialization efforts primarily on the United States spine and orthopedic markets. Its products remain subject to clinical development and regulatory approval, and the company has not established a broad portfolio of commercially marketed products based on the available information.View Bone Biologics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
